CXR Biosciences is now Concept Life Sciences. To keep up to date with our news at Concept Life Sciences, please follow Concept Life Sciences Integrated Discovery & Development Division page: https://www.linkedin.com/company/11052107 CXR Biosciences provides preclinical services and expertise, specialising in investigative toxicology, exploratory and discovery toxicology, metabolism and pharmacokinetics: - Investigative & Mechanistic Toxicology: by understanding the pathways that define the sensitivity of organs and cells to chemicals, we explain observed toxicities and evaluate the actual hazard and/or risk to humans. We have extensive experience in evaluating toxicological processes across species, and determining the relevance to humans of observed adverse reactions to the satisfaction of regulatory bodies. - Exploratory & Discovery Toxicology: R&D failure due to unexpected toxicity is a leading cause of attrition in the agrochemical, chemical and pharmaceutical industries. In order to improve productivity, identification of potential toxic hazard and quantification of potential risk is shifting from the development stage to the research stage of R&D. We use mechanistic toxicology at the research stage to drive chemical design, candidate selection and translational risk assessment. - Metabolism & PK/TK Support: a full understanding of the metabolism of compounds is required in the biological systems to which the product will be exposed (for example aos mandated by Regulation EC 1107/2009 for agrochemicals). CXR Biosciences routinely works with agrochemical, chemical and pharmaceutical companies to generate metabolic profiling data for new products, data gap fill and update to new regulations to supprt resubmissions.